News › Industry News

Lilly Files Lawsuit Against Indianapolis Spa for Selling Repackaged Zepbound

April 10, 2025

According to a lawsuit filed by Eli Lilly on Monday, April 7, a spa based in Indianapolis buys autoinjector pens filled with tirzepatide, cracks them open—breaking a sterile seal—and repackages them into lower unsterile doses.

On its website, the business offers deals for “brand name GLP-1 weight loss injections,” selling Lilly’s Zepbound for $350 a month and Novo Nordisk’s diabetes med Ozempic (semaglutide), which has also—against its drug label—been doubled up as a weight loss med, for $300 a month. 

In the complaint, which was filed in federal court in the Southern District of Indiana, Lilly says the spa’s advertising “explicitly contrasts the products it offers from the knock-off, untested, and unapproved products offered by other compounding pharmacies and med spas.”

Read more at Fierce Pharma >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Retatrutide Phase 3 Trial: Adults With Type 2 Diabetes Lost Average of 50 Pounds
    • Medical Marketing Whiz Recognized With Healthcare Digital Marketing Excellence Award
    • Allergan Presents Early Data on Skin Quality Treatments for Patients Taking Weight-Loss Medications
    • ValueCap Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s
Advertisement